

Ref: Syn/CS/SE/MPS/May 2018

Syngene International Limited
Biocon Park SEZ, Bommasandra IV Phase,
Jigani Link Road, Bangalore 560 099, India.
T +91 80 2808 2808
F +91 80 4014 3150 / 2852 3423
CIN No. L85110KA1993PLC014937

www.syngeneintl.com

May 15, 2018

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Sale of shares of the Company by the Promoter “Biocon Limited” in the Open Market for achieving Minimum Public Shareholding

In accordance with the requirements of Rules 19(2)(b) and 19(A) of the Securities Contracts (regulations) Rules, 1957 and Regulation 38 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with Para 2(a) and Para (3) of the SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 (“the Circular”) in connection with manner of achieving minimum public shareholding, we wish to inform the following details with respect to the intention of our Promoter, Biocon Limited, for sale of equity shares of the face value of Rs. 10/- each of Syngene International Limited (“the Company”), as per the following details:

S. No.	Details of the events to be provided	Information of such event
1	Intention of the Promoter/ Promoter Group to sell and the purpose of sale	Biocon Limited, our Promoter has conveyed to us their intention to sell the equity shares of face value of Rs. 10/- each of the Company to enable us to comply with the requirements of minimum public shareholding
2	Details of the Promoter/ Promoter Group, who propose to divest their shareholding	Biocon Limited, the Promoter of the Company proposes to divest part of its shareholding in the Company.



3	Total number of shares and percentage of shareholding proposed to be divested	Up to 2% of the total paid up equity share capital of the Company aggregating to 4,000,000 shares.
4	Period within which the entire divestment process will be completed ("Period")	Period beginning from May 16, 2018 to August 10, 2018 or the actual date of completion, whichever is earlier.


Undertaking received from the Promoter pursuant to Para 3(b) of the Circular is attached as annexure 1.

Request you to take the same on record.

Yours faithfully,


For SYNGENE INTERNATIONAL LIMITED

For Mayank Verma
Company Secretary



Anil Kumar Panchariya
Asst. Company Secretary





Date: 15th of May 2018

To,
The Compliance officer
Syngene International Limited
Biocon Park, SEZ,
Bommasandra Industrial Area - Phase-IV,
Bommasandra-Jigani Link Road,
Bengaluru, 560099
Karnataka

Biocon Limited

20th KM Hosur Road

Electronics City

Bangalore 560 100, India

T 91 80 2808 2808

F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

Sub: Undertaking in connection with Sale of equity shares of Syngene International Limited in the Open Market.

Dear Sir

In connection with the aforesaid subject and in accordance with Para (3) (b) of the SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 dealing with manner of achieving minimum public shareholding, we hereby undertake that:

“Biocon Limited or any persons belonging to the promoter group, shall not buy any shares in the open market on the dates on which the shares of Syngene International Limited are being sold by Biocon Limited as specified in the notice to the exchanges for the purpose of achieving minimum public shareholding requirement.”

This undertaking is issued to enable you to submit to Stock Exchange (s) along with the intimation of proposed sale of shares.

Thanking You,
Yours faithfully
For Biocon Limited


Dr. Arun Chandavarkar
CEO & Jt. Managing Director